



Emilio Fernandez-Egea M.D., PhD.

Date of Birth: 31st August 1973

CV as per September 2020

Position: Consultant Psychiatrist – Cambridgeshire and Peterborough NHS Foundation Trust. Associated Lecturer. Department of Psychiatry. University of Cambridge
Mental Health Speciality lead NIHR-CRN: Eastern

Address: Clozapine Clinic. 128 Tenison Road | Cambridge CB1 2DP UK.
Phone: + 44 (0)1223 516969/
e-mail: emilio.fernandez@cpft.nhs.uk / ef280@cam.ac.uk / emilio.fernandez@nihr.ac.uk
website: <http://www.psychiatry.cam.ac.uk/f20> / Twitter: [@EFernandezEgea](https://twitter.com/EFernandezEgea)

Private Practice: www.cambridgepsychiatry.co.uk

CV's Summary

Clinical academic with main interest in schizophrenia and psychosis. I completed my psychiatry training in Barcelona (Spain) in 2003 and moved to Cambridge in 2007. Since 2011, I lead the chronic schizophrenia team and recently the Cambridge Psychosis Centre.

I was the Associate Clinical Director for the WT/MRC Behavioural and Clinical Neuroscience Institute (BCNI), University of Cambridge (UoC) between 2011 and 2015. I am associated lecturer at the Department of Psychiatry (UoC), Mental Health Speciality lead for the Comprehensive Research Network NIHR-CRN and member of the NIHR-HTA program funding committee for large UK-based clinical trials.

Translating the research into novel clinical care interventions is paramount for me. The epidemiological and experimental research has led to new clinical protocols, from setting the clozapine community initiation to novel CBT interventions for Clozapine-induced OCD, among others. We also have expertise in commercial and non commercial clinical trials and collaborations within UoC, UK centers and abroad.

From the research point of view, my research career covers +100 original manuscripts (h-index~33 and +3,200 citations, different sources). My PhD focused on neuroscience and then moved to the molecular pathways that links schizophrenia with rest of the body, which was a main line of research (inflammation, ageing and metabolism), with over +40 original research papers on this topic, but more recently I focused on exploring factors associated with mental comorbidity in schizophrenia, with particular interest in neuroscience of negative symptoms and comorbid obsessive-compulsive disorder. My research has been funded by NARSAD (Young investigator award), NIH (RO1), NIHR-BRC and NIHR-HTA, among others. I have also received a number of awards for my clinical work (Clinical Excellent Awards), research and PhD, and for the book for general public about schizophrenia (in Spanish, +10,000 copies).

Education

1997 Bachelor Medicine, Universidad Autonoma Barcelona, Spain.
2003 CCT, Specialist in Psychiatry, Hospital Clinic, Barcelona, Spain
2006 DSc in Statistics for Health Science. Universidad Autonoma Barcelona, Spain.
2010 PhD in Neuroscience, Universidad de Barcelona, Spain.

Professional

Dates	Position	Institution	Field of work
07/03 – 11/07	Consultant Psychiatrist -PT	Hospital Clínic, Spain	Schizophrenia
01/08 – 09/11	Consultant Psychiatrist -FT	Huntingdon – CPFT* ²	Rehab and Early Intervention
10/11 – 02/15	Associate Clinical Director	BCNI – U. Cambridge	Behavioural and Clinical Neuroscience Institute.
10/11 -	Consultant Psychiatrist* ²	Cambridge - CPFT	Clozapine Clinic and General Adult

PT: (Part-time), FT: Full-time, L: Locum, *CPFT: Cambridgeshire and Peterborough NHS Foundation Trust.

*²: substantive post, ranging from 2 to 10 PAs depending the period. Currently, 12.5 PAs.

Professional societies

2020 – British Association for Psychopharmacology (BAP).
 2018 – European College Neuropsychopharmacology (ECNP).
 2018 – Accredited University lecturer by the Spanish Agency for Academic Quality (ANECA).
 2018 – Accredited University lecturer by the Catalan Agency for University Quality (AQU),
 2011 – Specialist Associate of the Royal College of Psychiatrists.
 2007 – General Medical Council (6162903) – Specialist Register – Revalidated 2016.
 Past memberships: British Neuroscience Association (2011-2013). Early Intervention Society (2007-2011).
 Sociedad Española Psiquiatría [Spanish Psychiatry Society; 2007-2019], *Schizophrenia International Research Society* (SIRS; 2006-2014).

Research Networks membership

2018 – Treatment Response and Resistance in Psychosis (TRRIP) (Prof. Howes led)
 2018 – ECNP Schizophrenia Network (Prof Galderisi led)
 2006 – 2019 CIBERSAM (Spanish Network for Mental Health Research)

Prizes and awards

2011 to 2019; NHS Clinical Excellent Awards: Currently 4.
 2013 – Associate Award. Mental Health Research Network.
 2013 – CPFT Staff Award / Research, Innovation and Education Award.
 2011 – Best Doctoral Thesis 2009-2010 by the Spanish Society of Biological Psychiatry.
 2009 – Young Investigator Award: Spanish Society of Biological Psychiatry. Award to the manuscript entitled: “Parental History of Type 2 Diabetes in Patients with Nonaffective Psychosis”.
 2009 – Young Investigator Award CIBERSAM (Spanish Research in Mental Health Network) for best presentation. Santander 13th Nov 2009.
 2005 - IX Jaime Albert Solana (FEAFES) national award to the best book published in divulgation in mental health. FEAFES is the national (Spanish) federation of supporting groups and charities in mental health. Title of the book is “Schizophrenia: from chaos to hope”. More than 10,000 copies have been sold and a second edition is under preparation.

Grants (italics denotes completed)

Title	Role	Funder	Period	Amount
Sound and Vision: a collaboration between service users, artists and the public to explore the lives experience of hallucinations	Co-I; CI: J. Suckling / C. Rollins	Guarantors of Brain	2020-	£6,000
ATLANTIS: Anticonvulsant Augmentation Trial in Schizophrenia	PI; CI: O. Howes	NIHR-HTA 127755	2020-	£1,700,000
Genetics of Common Clozapine Side Effects	PI & CI	CPFT – NIHR-BRC	2018-20	£13,000
Clinical and Research database	PI & CI	CPFT – NIHR-BRC	2012-	£28,000
<i>Immune-phenotyping active schizophrenia: a pilot study'</i>	PI CI: ET. Bullmore	CPFT – NIHR-BRC	2012-14	£99,000
<i>Molecular Markers of Aging in Psychosis</i>	PI CI: P.J. Jones	NARSAD – Young Investigator Award	2009	\$60,000
<i>Diabetes in neuropsychiatric disorders</i>	Co-I; CI: B. Kirkpatrick	NIH – NIDDK RO1	2005-10	€1,400,000
<i>Diabetes in neuropsychiatric disorders</i>	PI CI: B. Kirkpatrick	NARSAD - Young Investigator Award	2004	\$60,000
<i>Study with PET-¹⁸F-FDG of limbic metabolism among deficit vs. nondéficit schizophrenia</i>	PI; CI: E Parellada & M. Bernardo	Hospital Clinic Barcelona – Post residency award	2003-05	€40,000

Member of boards, committees, commissions,

2020 – Wellcome Trust Flagship Initiative Advisory board.
[2020 – NIHR Mental Health Urgent Public Health Group \(CoVid19 MH research\)](#)
 2020 – Associate editor: Revista Psiquiatría y Salud Mental
 2019 – NIHR-HTA funding committee full member (~£100M annual allocation budget)
 2019 – Comprehensive Psychiatry – editorial board.
 2019 – POMH – RCPsych – Prescription observatory in mental health – audit of prescriptions in UK.

2013 – CPFT Clozapine Initiation Committee (chair).
 2013 – 2015 Healthy and Safety officer for the Department of Psychiatry.
 2011 – 2015 Clinical Committee – Herchel Smith Building. BCNI representative.
 2009 – 2010 Committee for Revalidation & ReCertification –Spanish Biological Psychiatry Society.
 2009 – 2010 Recovery and Rehabilitation team. Cambridge and Peterborough Foundation Trust. Huntingdon
 2008 – 2012 Drug and Therapeutics Committee. Cambridgeshire and Peterborough NHS Foundation Trust.
 2008 – Clozapine Clinic – Cambridge and Peterborough Foundation Trust.

Other merits

Peer reviewer for journals: *Schizophrenia Research* (2010-), *Biological Psychiatry* (2010-), *Journal Affective Disorders* (2010-), *Psychiatry Research* (2010-), *Expert Review of Neurotherapeutics* (2010-), *Revista de Psiquiatria y Salud Mental* (2010-), *Clinical Schizophrenia & Related Psychosis* (2009-), *Neuropsychobiologia* (2009-), *European Archives of Psychiatry and Clinical Neuroscience* (2008-), *Acta Psychiatrica Scandinavica* (2017-); *European Neuropsychopharmacology* (2015-); *Psychological Medicine* (2014-), *Comprehensive Psychiatry* (2016-), *Schizophrenia Bulletin* (2005-) and *British Journal of Psychiatry* (2020-); and agencies: National Institute of Health Research (NIHR), Agencia Qualitat Universitaria (2017-); Wellcome Trust (2013-) and Medical Research Council (2016-)

Publications:

Total number of publications, divided by periods (pre/post PhD), relevance measured by quartiles (Q1 denotes top 25% medical journals) and role in the research in brackets (number of originals in which I was first, second and/or corresponding author).
 h-index: 33; total citations: ~3,100 ([Google Scholar](#))
 h-index: 26; total citations: ~2,000 ([Scopus](#))

	Pre-PhD	Post PhD	
	2000-2009	2010-2019	2020-
Q1	12 (8)	41 (15)	12 (7)
Q2	6 (3)	9 (4)	
Q3	6 (0)	6 (3)	
Q4	5 (1)		

Key publications (7)

Fernandez-Egea E. One hundred years ago: Nijinsky and the origins of schizophrenia. *Brain*, 2019; 142(1):220-226

Kirkpatrick B, Gurbuz O, Delice M, Hack G, Fernandez-Egea E. An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia. *Schizophrenia Bulletin* 2019; 45(6):1331-1335.

Fernandez-Egea E, Worbe Y, Bernardo M, Robbins TW. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. *Psychological Medicine* 2018; 48(16):2668-2675.

Fernandez-Egea E, Garcia-Rizo C, Zimbron J, Kirkpatrick B. Diabetes or Prediabetes in Newly Diagnosed Patients With Nonaffective Psychosis? A Historical and Contemporary View. *Schizophr Bull.* 2013; 39(2):266-267.

Fernandez-Egea E, Bernardo M, Conget I, Donner T, Parellada E, Esmatjes E, Kirkpatrick B. The Metabolic Profile of Antipsychotic-Naïve Patients with Nonaffective Psychosis. *British Journal of Psychiatry* 2009; 194 (5):434-438.

Fernández-Egea E, Bernardo M, Parellada E, Donner T, Kirkpatrick B et al. Telomere length, pulse pressure and glucose metabolism in schizophrenia. *Schizophrenia Bulletin* 2009; 35(2):437-442.

Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Stem Cell Signalling in Psychosis. *Mol Psychiatry* 2009; 14 (11): 989-991

Complete list

1. Rose E, Chen S, Turrion C, Jenkins C, Cardinal RN, **Fernandez-Egea E.** Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study. *Eur Neuropsychopharmacology* 2020 (in press).

2. Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Lee J, Falkai P, Schneider-Axmann T, Hasan A; **TRIP Working Group***. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRIP) Working Group. *Schizophr Bulletin* 2020 (in press).
3. Martínez-Cao C, García-Álvarez L, Bobes-Bascarán T, de la Fuente-Tomás L, **Fernández-Egea E**, Velasco Á, González-Blanco L, Zurrón-Madera P, Fonseca-Pedrero E, Sáiz-Martínez PA, García-Portilla MP, Bobes J. Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. *Rev Psiquiatr Salud Ment.* 2020 Jun 4:S1888-9891(20)30033-1. doi: 10.1016/j.rpsm.2020.04.008
4. **Fernandez-Egea E**, Walker R, Ziauddeen H, Cardinal RN, Bullmore ET. Birth weight, family history of diabetes and diabetes onset in schizophrenia. *BMJ Open Diabetes Research and Care.* 2020 (in press) 10.1136/bmjdr-2019-001036
5. Toll A, Berge D, Burling K, Scoriels L, Treen D, Montserrat C, Marmol C, Duran X, Jones PB, Perez-Sola V, **Fernandez-Egea E**, Mane A. Cannabis use influence on peripheral brain-derived neurotrophic factors levels in antipsychotic-naïve first-episode psychosis. *Eur Arch Psychiatry Clin Neurosci*, 2020 (in press).
6. Atkinson-Clement C, Sofia F, **Fernández-Egea E**, de Liege A, Béranger B, Klein Y, Deniau E, Flamand E, Hartmann A, Worbe Y. Structural and functional abnormalities within sensori-motor and limbic networks underpin intermittent explosive symptoms in Tourette disorder. *J Psych Res* 2020, in press.
7. Jarratt-Barnham I, Saleh Y, Husain M, Kirkpatrick B, **Fernandez-Egea E**. The influence of negative and affective symptoms on anhedonia self-report in schizophrenia. *Comprehensive Psychiatry* 2020 (in press).
8. Dal Santo F, Jarratt-Barnham I, González-Blanco L, García-Portilla MP, Bobes J, **Fernández-Egea E**. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: a mediation model. *Eur Neuropsychopharmacology* 2020 (in press).
9. Daniels ND, **Fernandez-Egea E**. Sleepwalking associated with clozapine treatment: two cases. *J Clin Psychopharmacology* 2020 (in press).
10. García-Rizo C, Bioque M, Mezquida G, Amoretti A, Cuesta MJ, Díaz-Caneja CM, Mas S, Lobo A, González-Pinto A, Fraguas D, Corripio I, Vieta E, Baeza I, Berge D, **Fernandez-Egea E**, Garriga M, Bernardo M and PEPs GROUP. Birth weight and antipsychotic induced weight gain: a prenatal programming approach in the PEPs study. *Schizophr Res*, 2020 (in press)
11. Mezquida G, **Fernandez-Egea E**, Treen D, Mane A, Berge D, Savulich G, Garcia-Alvarez L, Garcia-Portilla MP, Bobes J, Bernardo M, Garcia-Rizo M. Difficulties in delivery and depressive symptomatology in schizophrenia. *Rev Psiquiatr Salud Mental* 2020 (in press).
12. Kirkpatrick B, Gurbuz O, Delice M, Hack G, **Fernandez-Egea E**. An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia. *Schizophrenia Bulletin* 2019; 45(6):1331-1335.
13. Biriá M, Huang FX, Worbe Y, Fineberg NA, Robbins TW, **Fernandez-Egea E**. A cross sectional study of impact and risk factors of antipsychotic-induced OCD. *Eur Neuropsychopharmacol* 2019; 29(8):905-913.
14. Turrion MC, Perez J, Bernardo M, **Fernandez-Egea E**. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. *Rev Psiquiatr Salud Mental* 2020; 13(1):31-35.
15. Garriga M, **Fernandez-Egea E**, Mallorqui A, Serrano L, Oliveira C, Parellada E, Kirkpatrick B, Vieta E, Bernardo M, Garcia-Rizo C. Antipsychotic-induced weight gain and birth weight in psychosis: a fetal programming model. *J Psychiatr Res* 2019; 115:29-35.

16. Scoriels L, Zimbron J, Garcia-Leon N, Coll-Negre M, Giro M, Perez J, Jones PB, **Fernandez-Egea E**. Cross-sectional study of diet patterns in early and chronic schizophrenia. *Schizophrenia Research* 2019; 208:451-453.
17. **Fernandez-Egea E**. One hundred years ago: Nijinsky and the origins of schizophrenia. *Brain*, 2019; 142(1):220-226.
18. Nestor LJ, Paterson LM, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Ersche KD, Suckling J, Elliott R, Deakin B, Rabiner I, Lingford Hughes A, Sahakian BJ, Robbins TW, Nutt DJ; **ICCAM Consortium**. Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and poly-substance dependent individuals. *Eur J Neuroscience* 2019; 50(3): 2311-2321.
19. Mezquida G, **Fernandez-Egea E**, Treen D, Mane A, Berge D, Savulich G, Garcia-Alvarez L, Garcia-Portilla P, Bobes J, Bernardo M, Garcia-Rizo C. Obstetric phenotypes in the heterogeneity of schizophrenia. *J Nerv Ment Dis*, 2018: 206(11):882-886.
20. Treen D, Savulich G, Mezquida G, Garcia-Portilla MP, Toll A, Garcia-Rizo C, Garcia-Alvarez L, Berge D, Bobes J, Bernardo M, **Fernandez-Egea E**, Mane A. Influence of secondary sources in the brief negative symptom scale. *Schizophrenia Research*. 2019; 204:452-454.
21. **Fernandez-Egea E**, Worbe Y, Bernardo M, Robbins TW. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. *Psychological Medicine* 2018; 48(16):2668-2675.
22. Ahmed A, Kirkpatrick B, Galderisi S, Mucci A, Maj M, Rossi A, Bertolino A, Rocca P, Kaiser S, Bischof M, Hartmann M, Kirschner M, Schneider K, Garcia-Portilla MP, Mane A, Bernardo M, **Fernandez-Egea E**, Jiefeng C, Jing Y, Gold JM, Allen DN, Strauss GP. Cross-cultural validation of the five-factor structure of negative symptoms in schizophrenia. *Schizophrenia Bulletin* 2019 45(2):305-314.
23. Savulich G, Mezquida G, Atkinson S, Bernardo M, **Fernandez-Egea E**. Clozapine and cognition: friend or foe? *J Clin Psychopharmacology* 2018 Apr; 38(2):152-153.
24. **Fernandez-Egea E**, Kirkpatrick B. Correspondence regarding two recent publications in npj:schizophrenia about DNAm and accelerated aging in schizophrenia. *NPJ Schizophrenia* 2017 3(1):38 doi: 10.1038/s41537-017-0041-5.
25. Garcia-Rizo C, Casanovas M, **Fernandez-Egea E**, Oliveira C, Meseguer A, Cabrera B, Mezquida G, Bioque M, Kirkpatrick B, Bernardo M. Blood Cell count in antipsychotic-naive patients with non-affective psychosis. *Early Interv Psychiatry* 2017 (doi 10.1111/eip.12456). PMID: 28786532
26. Mezquida G, Savulich G, Garcia-Rizo C, Garcia-Portilla MP, Toll A, Garcia-Alvarez L, Bobes J, Mané A, Bernardo M, **Fernandez-Egea E**. Inverse association between negative symptoms and body mass index in chronic schizophrenia. *Schizo Res*. 2018 Feb;192:69-74; PMID: 28412089.
27. Apergis-Schoute AM, Gillan CM, Fineberg NA, **Fernandez-Egea E**, Sahakian BJ, Robbins TW. Neural Basis of impaired safety signaling in Obsessive Compulsive Disorder. *PNAS*. 2017 Mar 21;114(12):3216-3221.
28. Garrison JR, **Fernandez-Egea E**, Zaman R, Agius M, Simons JS. Reality monitoring impairment in schizophrenia reflects specific prefrontal cortex dysfunction. *Neuroimage Clin*. 2017 Jan 25;14:260-268.
29. Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Castro-Fornieles J, Bergé D, Escartí MJ, Ibañez Á, Penadés R, Sánchez-Torres AM, Bernardo M; **PEPs Group**. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. *Schizophr Res*. 2017 Feb 6. pii: S0920-9964(17)30060-9.

30. Anderson EJ, Tibber MS, Schwarzkopf DS, Shergill SS, **Fernandez-Egea E**, Rees G, Dakin SC. Visual Population Receptive Fields in People with Schizophrenia Have Reduced Inhibitory Surrounds. *J Neurosci*. 2017 Feb 8;37(6):1546-1556.
31. Garcia-Rizo C, **Fernandez-Egea E**, Bernardo M, Kirkpatrick B. Metabolic syndrome or glucose challenge in first episode of psychosis? *Eur Psychiatry* 2017 Mar; 41:42-46.
32. **Fernandez-Egea E**, Vertes PE, Flint SM, Turner L, Mustafa S, Hatton A, Smith KG, Lyons PA, Bullmore ET. Peripheral Immune Cell Populations Associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. *PLOS One*, 2016: 11(5):e0155631.
33. Mezquida G, Penades R, Cabrera B, Savulich G, Lobo A, Gonzalez-Pinto A, Penzol MJ, Corripio I, **Fernandez-Egea E**, Gasso P, Cuesta MJ, Bernardo M, PEPs group. Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia patients. *Eur Psychiatry* 2017 Oct;26(9):1353-1365.
34. Zimbron J, Khandaker G, Toschi C, Jones PB, **Fernandez-Egea E**. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. *Eur Neuropsychopharmacology* 2016 (in press).
35. Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Bernardo M, Kirkpatrick B. Meta-analysis of glucose tolerance, insulin and insulin resistance in antipsychotic-naive patients with nonaffective psychosis. *Schizo Res* 2017 Jan; 179:57-63.
36. Brown JE, Mezquida G, **Fernandez-Egea E**. Well-being in clozapine-treated schizophrenia patients: the significance of positive symptoms. *Compr Psychiatry* 2016;68:140-146.
37. Ziauddeen H, Garcia-Rizo C, Bernardo M, Kirkpatrick B, Ozanne SE, Jones PB, **Fernandez-Egea E**. Association of Birth Weight and the Development of Antipsychotic Induced Adiposity in Individuals with Schizophrenia. *Eur Neuropsychopharmacology* 2016; 26(6):972-978.
38. Gonzalez-Blanco L, Greenhalgh AM, Garcia-Rizo C, **Fernandez-Egea E**, Miller BJ, Kirkpatrick B. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. *Schizophrenia Res* 2016; 174(1-3):156-160.
39. Perdigués SR, Quecuti RS, Mané A, Mundell C, **Fernandez-Egea E**. An observation study of clozapine induced sedation and its management. *Eur Neuropsychopharmacol*. 2016; 26(1):156-61.
40. Sauras-Quecuti R, Ramos-Perdigues S, Mann L, **Fernandez-Egea E**. A study of clozapine-induced sedation. *Actas Esp Psychiatry* (in press).
41. Garcia-Rizo C, Kirkpatrick B, **Fernandez-Egea E**, Bernardo M. Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. *Psychoneuroendocrinology*. 2016 Feb 12;67:70-75.
42. Cardinal RN, Savulich G, Mann L, **Fernandez-Egea E**. Association between antipsychotic/antidepressant drug treatment and hospital admissions in schizophrenia assessed using a mental health case register". *Npj:schizophrenia* 2015 131(1):18-20.
43. Garcia-Portilla MP, Garcia-Alvarez L, Mané A, Garcia-Rizo C, Sugranyes G, Bergé D, Bernardo M, **Fernández-Egea E**, Bobes J. "The negative syndrome of schizophrenia: Three -underlying components are better than two." *Schizophr Res* 2015; 166(1-3):115-118.
44. Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, **Fernandez-Egea E**, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Pasetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JW, Nutt DJ, Lingford-Hughes AR, ICCAM Platform (2015), "The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform

- for evaluating new drugs for relapse prevention in addiction. Part A: Study description." *J Psychopharmacol* 2015; 29(9): 943-960.
45. Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, Hafizi S, Perez J, **Fernandez-Egea E**, Suckling J, Jones PB. "The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people." *Philos Trans R Soc Lond B Biol Sci* 2015; 370(1677).
 46. Worbe Y, Palminteri S, Savulich G, de Wit S, **Fernandez-Egea E**, Robbins TW, Voon V. Valence-dependent influence of serotonin depletion on model-based choice strategy. *Mol Psychiatry* 2016; 21(5):624-629.
 47. Garcia-Rizo C, **Fernandez-Egea E**, Bernardo M, Kirkpatrick B. The thrifty psychiatric phenotype. *Acta Psychiatrica Scandinavica* 2015, 131(1):18-20
 48. Worbe Y, Savulich G, deWitt S, **Fernandez-Egea E**, Robbins TW. Tryptophan depletion promotes habitual over goal-directed control of appetitive responding in humans. *International Journal of Neuropsychopharmacology* 2015; 18(10):pyv013.
 49. Mane A, Garcia-Rizo C, Garcia-Portilla MP, Berge D, Sugranyes G, Garcia-Alvarez L, Bernardo M, Bobes J, **Fernandez-Egea E**. Spanish adaptation and validation of the Brief Negative Symptoms Scale. *Comprehensive Psychiatry* 2014 55 (7):1726-1729.
 50. Ellison-Wright I, Nathan PJ, Bullmore ET, Zaman R, Dudas R, Agius M, **Fernandez-Egea E**, Muller U, Dodds CM, Forde N, Scanlon C, Leemans A, McDonald C, Cannon DM. Distribution of tract deficits in schizophrenia. *BMC Psychiatry*. 2014; 14(1):99.
 51. Worbe Y, Savulich G, Voon V, **Fernandez-Egea E**, Robbins TW. Serotonin depletion induces "waiting impulsivity" on the human Four Choice Serial Reaction Time Task: Cross-species translational significance. *Neuropsychopharmacology* 2014; 39(6):1519-26.
 52. Horga G, **Fernandez-Egea E**, Mane E, Font M, Schatz K, Falcon C, Lomena F, Bernardo M, Parellada E. Brain metabolism during hallucination-like auditory stimulation in schizophrenia. *PLoS One* 2014; 9(1):e84987.
 53. Kaser M, Soltesz F, Lawrence P, Miller S, Dodd C, Croft R, Dudas R, Zaman R, **Fernandez-Egea E**, Muller U, Dean A, Bullmore E, Nathan P. Oscillatory Underpinnings of Mismatch Negativity and their Relationship with Cognitive Function in Patients with Schizophrenia. *PLoS One* 2013; 8(12):e83255.
 54. **Fernandez-Egea E**, Scoriels L, Theegala S, Giro M, Ozanne SE, Burling K, Jones PB. Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2013; 46:25-28.
 55. Garcia-Rizo C, Kirkpatrick B, **Fernandez-Egea E**, Oliveira C, Meseguer A, Grande I, Undurraga J, Vieta E, Bernardo M. "Is bipolar disorder an endocrine condition?" Glucose abnormalities in bipolar disorder. *Acta Psychiatr Scand*. 2014; 129(1):73-4.
 56. Kirkpatrick B, Miller B, Garcia-Rizo C, **Fernandez-Egea E**. A conceptual model of schizophrenia. *Clinical Schizophrenia and Related Psychosis Journal* 2014; 8(2):73-79.
 57. Batalla A, Garcia-Rizo C, Castellvi P, **Fernandez-Egea E**, Yucel M, Parellada E, Kirkpatrick B, Martin-Santos R, Bernardo M. Screening for substance use disorders in first-episode psychosis: implications for readmission. *Schizophrenia Research*. 2013;146(1-3):125-31.
 58. **Fernandez-Egea E**, Garcia-Rizo C, Zimbron J, Kirkpatrick B. Diabetes or Prediabetes in Newly Diagnosed Patients With Nonaffective Psychosis? A Historical and Contemporary View. *Schizophr Bull*. 2013; 39(2):266-267.
 59. Garcia-Rizo C, **Fernandez-Egea E**, Miller BJ, Oliveira C, Justicia A, Griffith JK, Heaphy CM,

- Bernardo M, Kirkpatrick B. Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. *Brain Behav Immun*. 2013; 28:49-53.
60. Garcia-Rizo C, **Fernandez-Egea E**, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs nondeficit features. *Psychiatry Research* 2012; 198(2):212-5.
61. Pons A, Romero A, Goti J, **Fernandez-Egea E**, Undurruaga J, Carne X, Bernardo M. Should obesity be a limiting factor for clozapine treatment? *Rev Psiquiatr Salud Ment* 2013; 6(2): 75-79.
62. **Fernandez-Egea E**, Parellada E, Sugranyes S, Horga G, Lomena F, Falcon C, Pavia J, Bernardo M. Left Amygdalar Activation With Deficit Syndrome compared to Non-Deficit Subjects During the Control Task in a Facial Emotion Recognition Paradigm. *Psychiatry Research* 2012 Jul 30;203(1):109-10
63. Pintor L, Valdeoriola F, **Fernandez-Egea E**, Sanchez R, Rami L, Tolosa E, Muniz A, Marti MJ, Bernardo M. Utility of the Electroconvulsive Therapy in Parkinson's Disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study. *J ECT*. 2012 Jun;28(2):87-91.
64. **Fernandez-Egea E**, Garcia-Rizo C, Miller B, Justicia A, Parellada E, Bernardo M, Kirkpatrick B. Testosterone in Newly Diagnosed, Antipsychotic-Naïve Men with Nonaffective Psychosis: A Test of the Accelerated Aging Hypothesis. *Psychosom Med*. 2011 Oct;73(8):643-7.
65. Garcia-Rizo C, **Fernandez-Egea E**, Oliveira C, Justicia A, Parellada E, Bernardo M, Kirkpatrick B. Prolactin in first episode of non affective psychosis: gender differences and implications. *Schizophrenia Research* 2012; 134 (1):16-19.
66. Mane A, Gallego J, Lomena F, Mateos JJ, **Fernandez-Egea E**, Horga G, Cot A, Pavia J, Bernardo M, Parellada E. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. *Psychiatry Res*. 2011; 194(1):79-84
67. **Fernandez-Egea E**, Miller B, Garcia-Rizo, Bernardo M, Kirkpatrick. Metabolic Effects of Olanzapine in Newly-Diagnosed patients with psychosis. *Journal of Clinical Psychopharmacology* 2011; 31(2): 154-159.
68. Horga G, Parellada E, Lomena F, **Fernandez-Egea E**, Mane A, Font M, Falcon C, Konova A, Pavia J, Ros D, Bernardo M. Differential brain glucose metabolic patterns in antipsychotic-naïve first-episode schizophrenia with and without auditory verbal hallucinations. *J Psychiatry Neurosci*. 2011 Sep;36(5):312-21.
69. Kirkpatrick B, Garcia-Rizo C, Tang K, **Fernandez-Egea E**, Bernardo M. Cholesterol and triglycerides in antipsychotic-naïve patients with nonaffective psychosis. *Psychiatry Research* 2010;178 (3): 559-561.
70. Kirkpatrick B, Miller BJ, Garcia-Rizo C, **Fernandez-Egea E**, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naïve patients with nonaffective psychosis confounded by poor health habits? *Schizophr Bulletin* 2012; 38(2):280-284
71. Serraga N, Bernardo M, Gutierrez F, Justicia A, **Fernandez-Egea E**, Allas M, Safont G, Contreras F, Gascon J, Soler-Insa PA, Menchon JM and Keefe RSE. Spanish Validation of the BACS (Brief Assessment in Cognition in Schizophrenia) in patients with schizophrenia and healthy controls. *European Psychiatry* 2011; 26(2): 69-73.
72. **Fernandez-Egea E**, Parellada E, Lomeña F, Falcon C, Pavia J, Bernardo M. Amygdalar dysfunctional hyperactivity in schizophrenic patients across facial emotional and non emotional recognition tasks. *European Archives of Psychiatry and Clinical Neuroscience* 2010; 260(1): 69-76.

73. **Fernandez-Egea E**, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Stem Cell Signaling in Psychosis. *Mol Psychiatry* 2009; 14 (11): 989-991.
74. Mané A, Falcon C, Mateos JJ, **Fernandez-Egea E**, Horga G, Lomeña F, Bargallo N, Bernardo M, Parellada E. Progressive gray matter changes in first episode schizophrenia: a 4 year longitudinal magnetic resonance study using VBM. *Schizophrenia Research* 2009; 114 (1-3):136-143.
75. Cardinal RN, Shah DN, Edwards C, Hughes GRV, **Fernandez-Egea E**. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. *British Journal Psychiatry* 2009; 195(3):272. Letter.
76. Sugranyes G, Flamarique I, Parellada E, Baeza I, **Fernandez-Egea E**, Bernardo M. Cannabis abuse and age of psychosis onset. *European Journal of Psychiatry* 2009; 24(5): 282-286.
77. **Fernandez-Egea E**, Bernardo M, Conget I, Donner T, Parellada E, Esmatjes E, Kirkpatrick B. The Metabolic Profile of Antipsychotic-Naïve Patients with Nonaffective. *British Journal of Psychiatry* 2009; 194 (5):434-438.
78. **Fernández-Egea E**, Bernardo M, Parellada E, Donner T, Kirkpatrick B et al. Telomere length, pulse pressure and glucose metabolism in schizophrenia. *Schizophrenia Bulletin* 2009; 35(2):437-442.
79. Kirkpatrick B, **Fernandez-Egea E**, Garcia-Rizo C, Bernardo M. Differences in Glucose Tolerance Between Deficit and Nondeficit schizophrenia. *Schizophrenia Research* 2009; 107:122-127.
80. **Fernandez-Egea E**, Parellada E, Lomeña F, Falcon C, Pavia J, Mané A, Valdes M, Bernardo M. Continuous emotional task selectively activates the left amygdala in healthy volunteers: ¹⁸FDG-Study. *Psychiatry research: neuroimaging* 2009; 171(3):199-206.
81. Parellada E, Lomena F, Font M, Pareto D, Gutierrez F, Simo M, **Fernández-Egea E**, Pavia J, Ros D, Bernardo M. Fluorodeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. *Nucl Med Commun* 2008 Oct; 29(10):894-900.
82. Kirkpatrick B, Messias E, Harvey PD, **Fernandez-Egea E**, Bowie CR. Is Schizophrenia a Syndrome of Accelerated Aging? *Schizophrenia Bulletin* 2008 Nov; 34:1024-1032.
83. **Fernandez-Egea E**, Bernardo M, Parellada E, Justica A, García-Rizo C, Conget I, Esmatjes E, Kirkpatrick B. Glucose Abnormalities in the Siblings of People with Schizophrenia. *Schizophrenia Research* 2008; Aug; 103(1-3):110-3.
84. **Fernandez-Egea E**, Miller B, Bernardo M, Donner T, Kirkpatrick B. Parental History of Type 2 Diabetes in Patients with Nonaffective Psychosis. *Schizophrenia Research* 2008; 1-3:302-306.
85. Kirkpatrick B, Hack GD, Higginbottom E, Hoffacker D, **Fernandez-Egea E**. Palate and dentition in schizophrenia. *Schizophrenia Research* 2007; 91:187-191.
86. Mateos JJ, Lomeña F, Parellada E, Font M, **Fernandez-Egea E**, Pavia J, Prats A, Pons F, Bernardo M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. *Psychopharmacology (Berl)* 2007; 191:805-811.
87. Pintor L, Bailles E, **Fernandez-Egea E**, Sanchez-Gistau V, Torres X, Carreno M, Rumia J, Matrai S, Boget T, Raspall T, Donaire A, Bargallo N, Setoain X. Psychiatric disorders in temporal lobe epilepsy patients over the first year after surgical treatment. *Seizure: European Journal of Epilepsy* 2007; 16:218-225.
88. Bernardo M, **Fernández-Egea E**, Torras A, Gutierrez F, Ahuir M, Arango C. Validation into Spanish of the Schedule for the Deficit Syndrome. [Adaptación y validación en castellano del Inventario para la Esquizofrenia Deficitaria]. *Medicina Clinica (Barc)* 2007;129:91-93.

89. Gomez-Gil E, **Fernández-Egea E**, Trilla A, Almela A. Relevance of routine luetic serological test in acute psychiatric patient [Relevancia de la serología luética en pacientes psiquiátricos agudos ingresados]. *Medicina Clínica (Barc)* 2007;129:77.
90. Mateos JJ, Lomena F, Parellada E, Font M, **Fernandez E**, Pavia J, Prats A, Bernardo M. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]. *Rev Esp Med Nucl.* 2006;25(3):159-165.
91. **Fernández-Egea E**, A. Ferrer del Alamo, M. Torrebadiell Buriel, A. Carrió Ybáñez. Velocardiofacial síndrome in consultant-liason psychiatry. [El Síndrome Velo Cardio Facial en el ámbito clínico.] *Letter. Actas Esp Psiquiatr.* 2006; 34(1):67-68.
92. Mateos JJ, Lomeña F, Parellada E, Font E, **Fernandez E**, Pavia J, Prats A, Pons F, Bernardo M. Decreased strial dopamine transporters binding assessed with [123I]FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. *Psychopharmacology* (2005) 181: 401–406.
93. Bailles E, Pintor L, **Fernández-Egea E**, Torres X, Matrai S, de Pablo J, Arroyo S. Psychiatric disorders, trauma, and MMPI profile in a Spanish simple of nonepileptic seizure patients. *Gen Hosp Psychiatry* 2004; 26(4):310-315
94. Bailles E, Pintor L, Torres X, **Fernández-Egea E**, de Pablo J, Arroyo S. Patología psiquiátrica en pacientes con pseudocrisis remitidos a una unidad de epilepsia de un hospital general. [Psychiatric disease in patients with psychogenic non-epileptic seizures referred from an epilepsy unit in a general hospital] Spanish. *Actas Esp Psiquiatr.* 2004 Mar-Apr; 32(2):76-81
95. Parellada E, Lomena F, Catafau AM, Bernardo M, Font M, **Fernández-Egea E**, Pavia J, Gutierrez F. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. *Psychiatry Res.* 2004; 130:79-84.
96. Gómez-Gil E, Vidal A, Panés J, Jaén J, Peri JM, **Fernández-Egea E**, Piqué JM. [Relationship between patient's subjective stress perception and the course of inflammatory bowel disease]. Spanish. *Gastroenterol Hepatol.* 2003; 26(7):411-6.
97. Font M, Parellada E, **Fernández-Egea E**, Bernardo M, Lomeña M. Neuroimaging of auditory hallucinations in schizophrenia. [Neuroimagen funcional de las alucinaciones auditivas en la esquizofrenia]. Review. *Actas Españolas de Psiquiatría.* 2003; 31: 3-9.
98. Gómez E, Trilla A, Corbella B, **Fernández-Egea E**, Pablo J, Ferrer J, Valdés M. Lack of clinical relevance of routine chest radiography in acute psychiatric admissions. *General Hospital Psychiatry* 2002; 24: 110-113.
99. **Fernández-Egea E**, Gómez Gil E, Corbella Santomà B, Salamero Baró M, Blanch J, Valdés Miyar M. Prevalence of HIV, BHV and CHV among acute psychiatric patients admitted. *Medicina Clínica (Barc)*, 2002; 119: 690-962.

Teaching

Educational seminars

- 1- Lecturer. Medical School. University of Cambridge. 'Schizophrenia', since 2012 –
- 2- Clozapine Awareness Workshop (CPFT) – Organiser in 2013, 2018 and 2019
- 3- Treatment Resistant Schizophrenia Workshop (Barcelona, Spain) Annually since 2013-2018.
- 4- Prof Stahl's Cambridge Psychopharmacology programme. Master Class. Years 2013 & 2014.
- 5- Coordinator. Neuroscience Research theme. Instituto para Altos Estudios Universitarios. Neurociencia. Curso 2012/2013.

Books and chapters:

- 1- Esquizofrenia. Del Caos mental a la esperanza. [Schizophrenia: from mental chaos to hope] Authors: E. Parellada y E. *Fernández-Egea*. Barcelona: Ed. Morales i Torres. 2004.

Curriculum Vitae

Awarded in 2005 with IX Jaime Albert Solana (FEAFES) national award to the best book published in divulgation in mental health.

- 2- Què sabem de l'Esquizofrènia? Guia per a familiars i pacients. [What do we know about schizophrenia?: A book for families and patients] Author: Miquel Bernardo. Collaborator: M. Teresa Plana, E. Fernández Egea, A. Torras. Barcelona: Ars Mèdica, 2004.

Key Lectures

- 2020 – Symptoms of schizophrenia treatment (link) – Department Psychiatry. UoCambridge.
- 2019 – [Nijinsky and the origins of schizophrenia \(link\)](#) – Department Psychiatry. UoCambridge

Other merits and media presence

1. Chief trainee at the Hospital Clinic training committee from 2000 to 2003.
2. Interviewed by “El Mundo”, most important newspaper in Spain.
<http://www.elmundo.es/elmundosalud/2011/11/04/neurociencia/1320412079.html>

Visiting other centers:

Maryland Psychiatric Research Center. Baltimore (EEUU). From March to April 2003. Learning the use of Schedule for the Deficit Syndrome (SDS). Mentor: Brian Kirkpatrick.



Emilio Fernandez-Egea